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Recent developments point to a critical role for calcium dysregulation in the pathogenesis of Alzheimer’s
disease. A novel calcium-conducting channel called CALHM1 is genetically linked to the disorder and
modulates Ab production. Calcium homeostasis has also been shown to be perturbed in dendritic
spines adjacent to amyloid plaques. Finally, new studies have elucidated the role by which presenilins
modulate calcium signaling, including effects on SERCA2b and gating of the IP3 receptor, and lead to Ab
production.Introduction
A role for calcium dysregulation in Alzheimer’s disease (AD) was
first postulated 20 years ago (Khachaturian, 1987), and subse-
quent experimental studies have identified two principle means
by which it impacts or is impacted by the disease. Altered
neuronal calcium homeostasis may affect the metabolism and
production of the pathological proteins associated with the
disease—amyloid-beta peptide (Ab) and the microtubule-asso-
ciated protein tau. Conversely, events downstream from the
accumulation of these pathological proteins may further exacer-
bate calcium dysregulation, causing synaptic dysfunction and
neurodegeneration—the neurobiological substrates underlying
the cognitive decline.
Following this hypothesis, the involvement of calcium in AD
was further substantiated with the recognition that clinical muta-
tions in the presenilin (PS1/2) genes associated with familial AD
(FAD) profoundly affect calcium release from the endoplasmic
reticulum (ER) stores as well as calcium entry through store-
operated channels (LaFerla, 2002). Although direct evidence
for calcium disruption in the brains of AD patients has so far
been technically challenging to obtain, circumstantial evidence
from postmortem brains has been reported, such as increases
in levels of calcium-dependent proteases (reviewed in Green
et al., 2007).
Researchers have traditionally turned to animal models of
disease to explore human disorders in a living system in which
invasive techniques could give answers to otherwise intracta-
ble questions, such as calcium dynamics in a living human
neuron. However, the involvement of calcium in Ab-producing
transgenic mouse models has been largely confounded by
the use of FAD-associated presenilin mutations that, by them-
selves, perturb neuronal calcium dynamics, and surprisingly,
calcium homeostasis has not yet been extensively studied in
amyloid precursor protein (APP)-overexpressing mice without
presenilin mutations. Twenty years since the first hypothesis
paper, a number of recent seminal papers show evidence for
(1) a role for calcium dysregulation in the initiation of the dis-
ease, (2) the downstream involvement of calcium in Ab-induced
synaptic dysfunction, and (3) novel mechanisms linking
presenilins and FAD-linked mutations to perturbed calcium
homeostasis.190 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.Calcium Regulation of Ab Production and Linkage to AD
Rare mutations in the APP and PS1/PS2 genes cause FAD by
affecting the accumulation of the Ab peptide. Ninety-nine per-
cent of AD cases are sporadic (SAD), with advancing age being
a prerequisite for disease development. Like FAD, SAD is
thought to be caused by the accumulation of the Ab peptide
that occurs as a consequence of poorly understood complex
genomic, proteomic, lipidomic, and environmental interactions.
For many years, it has been known that changes in calcium levels
and dynamics alter the metabolism and production of Ab (re-
viewed in Green et al., 2007), implicating calcium dysfunction
as a possible causative factor in SAD.
By screening genes located in known AD linkage regions,
Philippe Marambaud and colleagues discovered a novel cal-
cium-conducting channel, with polymorphisms associated with
increased risk for the development of SAD (Dreses-Werringloer
et al., 2008). The association of these polymorphisms with SAD
will require replication, but builds on a number of studies show-
ing how altering calcium homeostasis affects Ab production.
This calcium channel was found to be a conserved three-trans-
membrane domain containing glycoprotein, which they called
calcium homeostasis modulator 1 (CALHM1). Expression of
CALHM1 was found in all brain regions and cells of neuronal lin-
eage. CALHM1 localized predominantly to the ER but also exists
at the plasma membrane, where it forms a novel calcium influx
route to the cytosol, which is unaffected by specific blockers
of store-operated calcium influx or voltage-gated calcium chan-
nels but inhibited by nonspecific cation channel blockers such as
colbalt (Figure 1). CALHM1 appears to exist as multimeric com-
plexes, forming a functional ion channel, and has structural sim-
ilarities with the NMDA receptor within the ion selectivity region.
Critically, calcium influx through CALHM1 decreases Ab produc-
tion and is accompanied by increases in sAPPa. The mechanism
underling this effect is not elucidated but presumably involves
a calcium-dependent effect on an a-secretase—these are en-
zymes that are known to cleave APP 83 amino acids from the
carboxy terminus and thereby prevent Ab formation. Conversely,
increases in Ab occur after siRNA knockdown of endogenous
CALHM1 in cells when combined with calcium influx. Notably,
the authors identified a polymorphism in the CALHM1 gene
(rs2986017) causing a substitution of P86L, which decreases
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Cytosolic calcium levels are kept low (100 nM)
relative to the extracellular space and the intracel-
lular stores by the presence of calcium-binding
buffering proteins (e.g., calbindin), via the extru-
sion of cytosolic calcium across the plasma mem-
brane through calcium ATPase pumps and ex-
changers, and also due to sequestration into
intracellular stores such as the ER. Calcium influx
into the cytosol is a tightly control process, both
temporally and spatially, and occurs across the
plasma membrane via store-operated calcium
channels, voltage-gated calcium channels, the
newly identified CALHM1, or from internal stores.
The ER is the largest intracellular store, maintain-
ing a high calcium concentration (100–500 mM)
via the pumping of cytosolic calcium by SERCA.
Calcium release from the ER into the cytosol oc-
curs via two types of calcium channels: IP3Rs
and RyRs. IP3R-mediated release is regulated at
the plasma membrane by ligand binding to spe-
cific G protein-coupled receptors that induce
phospholipase C to cleave phosphatidylinositol-
4,5-bisphosphate into diacylglycerol and IP3,
which then binds to the IP3R in the ER membrane.
Dendritic spines also contain ER calcium stores,
and regulation of ER calcium is set by the actions
of SERCA, IP3Rs, and RyRs. Calcium influx across
the plasma membrane occurs due to depolariza-
tion, through VGCCs and glutamate receptors
such as the NMDA receptor and the metabotropic
glutamate receptor.
Presenilins are located within the ER membrane
but are also found at the plasma membrane and
other subcellular locations, and both wild-type
and FAD-associated mutants increase IP3R-medi-
ated calcium release, as well as modulate calcium regulation through both the RyR and SERCA. Mutant presenilins also impair endogenous calcium leak from the
ER, resulting in increased store content, while CALHM1 is located mainly in the ER and appears to possess properties associated with a passive leak channel.
APP is processed by either a-secretase, precluding Ab generation, or by b-secretase leading to Ab generation, after subsequent cleavage by the g-secreatse
complex. Calcium influx through CALHM1 promotes the a-secretase pathway and reduces Ab generation. Conversely, increased calcium entry into the cytosol
from the ER is associated with increased production of Ab.calcium permeability and also increases Ab production. If
replicated, this finding provides direct genetic evidence of a cal-
cium-conducting channel impacting the development of AD and
shows that calcium influx pathways can affect APP processing
to modulate the production of Ab.
The question of how calcium influx through CALHM1 affects
APP processing has not been addressed. The authors link the
P86L variant to SAD and also to impaired calcium permeability.
Is this calcium route novel on its effects on APP or does calcium
influx through any channel lead to similar effects on APP? Is it the
level of calcium within the cytosol that is important, or is it more
spatially regulated with regard to APP processing? The calcium
influx pathway associated with the P86L polymorphism in
CALHM1 decreases cytosolic calcium entry and is associated
with higher Ab levels. Curiously, this observation is contradictory
to the vast majority of studies published on cytosolic calcium
entry and Ab production, which indicate that increasing calcium
influx into the cytosol, either from the extracellular media or from
ER stores, increases Ab production (Green et al., 2007). Given
the inconsistency with previous data, calcium entry through
CALHM1 may represent a tightly controlled influx pathway with
novel spatial links to APP processing, which other cytosolic
calcium influx pathways do not seem to mimic.
The other unexplored possibility is that the effects of CALHM1
and the P86L variant exact their effects on Ab processing viatheir spatial location in the ER rather than the smaller pool found
on the plasma membrane, given that the vast majority of
CALHM1 was localized to the ER. It is unknown whether
CALHM1 forms a functional cation-conducting pore within the
ER, which could facilitate calcium influx or efflux from the stores.
Future experiments should determine whether expression of
CALHM1 affects ER calcium homeostasis and store levels. As
the channel appears to be constitutively open (as membrane
depolarization was not required for calcium influx), it may exist
as a potential leak channel at the ER, which would increase
cytosolic calcium and would be diminished by the P86L variant.
This finding would then be in agreement with previous studies
showing how ER calcium regulation modulates Ab production.
Calcium Dysregulation by Ab Accumulation
The question remains as to whether disturbances in calcium
homeostasis mediate any of the downstream events, which
lead from the aberrant production and accumulation of Ab to
cognitive decline and neurodegeneration. It is vital to not only ex-
amine global calcium dynamics within neurons in pathologically
affected areas, but also at discrete areas of neurons, such as the
dendritic spines, which contain many of the postsynaptic synap-
ses. This approach has been taken by Brian Bacskai and col-
leagues, who utilized an adeno-associated virus expressing
the YC3.6 ratiometric calcium indicator (Kuchibhotla et al.,Neuron 59, July 31, 2008 ª2008 Elsevier Inc. 191
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APP mouse models of AD, neurons were predominantly infected,
thereby allowing the visualization of dendritic spines and other
fine structures.
The study identified that plaque-containing transgenic mice
had significantly elevated numbers of neurites (ten times more)
with overloaded cytosolic calcium compared to age-matched
nontransgenic controls, although these overloaded neurites
represented only a small fraction of the total. This effect was inde-
pendent of any FAD-linked presenilin mutations present but was
positively correlated with the distance from Ab plaques. The
source of the calcium overload was refined further by comparing
the calcium load in the dendritic spine compartment with its im-
mediate adjacent dendrite. Spines function as discrete compart-
ments that can regulate the duration and spread of postsynaptic
calcium transients due to glutamatergic neurotransmission. The
induction of synaptic plasticity is dependent upon large rises in
postsynaptic calcium levels. By acting as a discrete compart-
ment, such rapid rises are possible and not translated through
to the adjacent dendrite—calcium entering the spine is rapidly
buffered and the remaining calcium quickly extruded with little
time for remaining calcium ions to diffuse into the dendrite. Under
physiological conditions, calcium levels in dendritic spines are
regulated distinctly from those in the nearby dendrite, thereby
allowing for independent calcium regulation. In areas close to
plaques, a large proportion of spines had elevated basal calcium
levels and had a strong correlation between the adjacent dendrite
calcium levels. This finding suggests that the local compartmen-
talization of the spines with regard to calcium homeostasis has
been lost and that spine calcium leaks out into the dendrite,
preventing spine/dendrite independent calcium signaling.
The resting calcium concentration in these overloaded spines
affected neurite morphology, with higher basal levels being as-
sociated with abnormal beaded morphology. These changes in
morphology were prevented by inhibiting the calcium/calmodu-
lin-dependent protein phosphatase 2B (calcineurin). Further-
more, spine motility is highly regulated by calcium levels, as
many of the proteins involved in F-actin remodeling are calcium
dependent (i.e., gelsolin), with increased calcium being associ-
ated with decreased motility and F-actin loss, which can be pre-
vented with calcineurin antagonists (Oertner and Matus, 2005).
These results highlight for the first time that proximity to Ab pla-
ques induces calcium dysregulation, and in discrete subcellular
compartments, which are relevant to learning and memory, LTP,
and synaptic loss. This seminal study provides data linking AD
pathology and calcium dysregulation with subsequent morpho-
logical changes and opens the door to a number of compelling
future studies. For example, it has been shown in many APP
transgenic animals that both behavioral deficits and LTP deficits
occur prior to extensive plaque deposition, albeit at ages when
elevated Ab and oligomeric Ab levels are measured. Does this
same neurite calcium overloading lead to the LTP and behavioral
deficits in these younger animals? In the current study, the au-
thors found no elevated neurite calcium in young APP/PS1
mice but did not examine this issue in Tg2576 mice at ages
before plaques but coincident with cognitive deficits.
The source of elevated basal cytosolic calcium in neurites in
close proximity to Ab plaques was unexplored by the authors.192 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.Basal calcium levels are tightly regulated by a number of calcium
pumps and binding proteins, which sequester free cytosolic
calcium so that it cannot affect local enzymes and signaling cas-
cades. Calcium enters the cytosol from the extracellular space
through calcium-conducting voltage-dependent ion channels,
such as voltage-gated calcium channels and glutamate recep-
tors such as AMPA and NMDA receptors and also through
store-operated calcium-entry channels, which are activated
through ER calcium-depletion signaling pathways. Calcium
can also enter the cytosol from intracellular stores such as the
ER, via IP3 and ryanodine receptors, as well as the mitochondria.
Conversely, cytosolic calcium is reduced via the presence of cal-
cium-binding proteins, such as calbindin, which act as buffers,
and also through the extrusion of calcium either into intracellular
stores, such as the ER via the sarco-endoplasmic reticulum
ATPase (SERCA), or out across the plasma membrane via plas-
malemmal calcium pumps and exchangers (Figure 1). What is
the source of the elevated basal cytosolic calcium proximal to
the Ab plaques? Future studies will narrow this down, but circum-
stantial evidence points us to a number of possibilities. The first
is the NMDA receptor—Ab oligomers bind to the NMDA receptor
and induce calcium influx (De Felice et al., 2007), whereas Ab-in-
duced LTP deficits are dependent upon the NMDA receptor
(Chen et al., 2002). Influx through the NMDA receptor also leads
to further calcium release into the cytosol from internal stores
within the spine (Emptage et al., 1999), which forms the major
component of spine calcium transients. Notably, the NMDA par-
tial antagonist memantine shows beneficial effects in moderate
to severe AD patients. Second, there is an age-related decrease
in the calcium-buffering protein calbindin, which is also de-
creased in APP transgenic mouse models (Palop et al., 2003).
Calbindin knockout mice have increased dendritic spine basal
calcium (Chard et al., 1993) and develop abnormal spine mor-
phologies (Vecellio et al., 2000). Finally, Ab oligomers induce
calcium influx across the plasma membrane through novel pores
leading to increased cytosolic calcium (Demuro et al., 2005).
Presenilins and Calcium Homeostasis
Fueling the fire for a role of calcium in the pathogenesis of AD,
FAD-associated mutations in the presenilins were also found
to enhance IP3-mediated calcium release from the ER stores,
as well as perturb calcium entry through store-operated chan-
nels (LaFerla, 2002). The presenilins were identified in 1995 as
multi-membrane-spanning proteins, which predominantly local-
ized to the ER, and were postulated to form a novel ion channel.
Their involvement in the pathogenesis of AD was cemented with
the discovery that the presenilins formed the catalytic core of the
g-secretase complex, which liberates Ab from the membrane
stub C99. These FAD mutations were found to shift the length
of the Ab to a more predominantly 42 amino acid long version,
which aggregates more readily. However, the role of these cal-
cium perturbations in the disease progression have been hotly
debated, as (1) such calcium-disturbing presenilin-dependent
effects do not occur in SAD and (2) the increased length of Ab
caused by presenilin mutations is sufficient to explain why these
mutations lead to FAD, as some mutations in APP have also been
identified that cause a similar shift in the length of Ab produced
(i.e., the London mutation) and are also associated with FAD.
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lin mutations on cellular calcium play no role in FAD progression,
or second, that while FAD presenilin mutations elongate Ab and
give rise to FAD the perturbations in calcium caused by the same
mutation further exacerbate the disease phenotype and/or
progression.
Whether or not FAD presenilin mutations perturbing calcium
homeostasis play a role in disease progression, the effects of
these mutations on calcium are striking and the subject of
some debate. Uniformly, these presenilin mutations have been
shown to enhance IP3-mediated calcium release from the ER
stores (LaFerla, 2002), and several hypotheses have been put
forward to explain this effect. Given that FAD presenilin muta-
tions enhance calcium release from the ER via the IP3 receptor
(Leissring et al., 1999), the ryanodine receptor via caffeine (Smith
et al., 2005), and through endogenous calcium leak channels (Tu
et al., 2006), it was thought that these results could all be ex-
plained by an increase in ER calcium load. These results have
been shown via overexpression in Xenopus oocytes (Leissring
et al., 1999), mammalian cell lines (Smith et al., 2002), primary
neuronal cultures (Smith et al., 2005), and slice imaging from
knockin mice (Stutzmann et al., 2007). However, the same
FAD-linked mutations have also shown a reduction in ER calcium
load and ER release with SERCA inhibition (Zatti et al., 2006), in-
cluding results from human fibroblast and rat neuronal cultures;
thus, it is unclear whether all mutations increase ER calcium or
not. Regardless of ER calcium load, all researchers have consis-
tently measured increased IP3-mediated calcium release with
FAD mutations.
Foskett and colleagues employed direct IP3 channel record-
ings via single-channel patch-clamp electrophysiology of the
ER membrane, expressing presenilin or FAD-linked mutants
(Cheung et al., 2008). Overexpression of mutant presenilin 1 or
2 directly increased IP3 channel activity in the presence of both
suboptimal and saturated [IP3] by prolonging the channel open
time. In comparison, wild-type presenilin overexpression had
only modest effects on IP3 channel activity. Increased IP3 recep-
tor gating accounted for the enhanced IP3 receptor-mediated
calcium release in the presence of presenilin FAD mutants, as
direct measurement of ER calcium stores showed either no
change or a modest reduction compared to control cells. Prese-
nilin mutants appear to modulate the IP3 receptors directly, as
they were found to physically interact and are known to colocal-
ize to the ER membrane, although it should be noted that this
interaction was observed with overexpression of hydrophobic
ER proteins, which could give false-positive results. These re-
sults show a novel interaction between presenilin FAD mutants
and the IP3 receptor, which are able to modulate gating activity
and affect global calcium dynamics, and are consistent with re-
cordings from mutant presenilin knockin mice fibroblasts that
show increased sensitivity to IP3 receptor agonists (Leissring
et al., 2000).
Such results add to a growing body of evidence that presenilin
FAD mutations affect ER calcium dynamics on multiple levels. In
addition to interacting with the IP3 receptor, presenilin have been
shown to interact with the ryanodine receptor, via its N terminus,
and to increase the open channel probability and mean current
(Rybalchenko et al., 2008), similar to that described with theIP3 receptor. Increased calcium release via the ryanodine recep-
tor has been described in a number of systems, including slice
recordings from FAD presenilin mutant knockin mice (Stutzmann
et al., 2007) and primary neuronal cultures (Smith et al., 2005)
and may be due to increased ryanodine receptor expression
and activity.
In addition to these ‘‘gain-of-function’’ interactions with native
ER calcium receptors, FAD-linked presenilin mutations have also
been shown to have a ‘‘loss-of-function’’ effect on ER calcium
dynamics by reducing endogenous calcium leak from the ER
(Tu et al., 2006). Such an effect would lead to increased ER
calcium load and overfilled ER stores and could explain the
increases in ER calcium release observed by many researchers
through a variety of routes, including IP3-mediated calcium
release. It was suggested that presenilins themselves form a cal-
cium leak channel in the ER, which is disrupted by FAD-linked
mutations. However, in the study by Foskett and colleagues,
no current through ER membrane was measured by patch
clamp, despite overexpression of wild-type or FAD-linked prese-
nilin mutants, in the absence of IP3, strongly arguing against
presenilin forming calcium leak channels (Cheung et al., 2008).
Clearly, FAD linked mutations in presenilins impact calcium on
multiple levels, and it is not clear which one lies upstream or why
different groups see opposing results with ER calcium load and
release with the same presenilin mutations. However, given
these profound effects that mutant presenilins have on cellular
calcium homeostasis, it is feasible to postulate that endogenous
presenilins play an integral role in calcium homeostasis, affecting
the normal physiological cell biology. Presenilin knockout cells
also display markedly perturbed calcium stores, typically re-
duced ER calcium stores, suggesting that the absence of prese-
nilin has devastating effects on calcium regulation (Green et al.,
2008). The physiological role that presenilins play in calcium
regulation may prove to be more important than understanding
how FAD-linked mutations affect calcium dynamics, but are
likely related. Elucidating whether endogenous presenilin affects
the gating of the IP3 or ryanodine receptor is crucial and can be
done without the disadvantages of using an overexpression
system, which could produce results that do not occur in normal
cellular physiology or even pathophysiology.
We recently demonstrated that cells lacking both presenilins
exhibit a phenotype similar to SERCA knockdown and that en-
dogenous presenilins interact with SERCA (Green et al., 2008).
Overexpression of wild-type presenilins also accelerates the
sequestration of cytosolic calcium, an effect that can be blocked
by pharmacological inhibition of SERCA, suggesting that prese-
nilins modulate SERCA function, and that SERCA pumping is im-
paired in the absence of both presenilins. Taken together, prese-
nilins appear to interact and modulate calcium influx into the ER
via SERCA, and calcium extrusion from the ER via interactions
with the ryanodine and IP3 receptors as well as through endog-
enous leak channels, and further experiments will be required
to show which interactions are mediated in an endogenous
role versus ones influenced by FAD mutant presenilins. Given
the complex intricacies associated with calcium dynamics, it is
likely that affecting any one of these calcium routes will have
consequences for the others. In addition, it needs to be eluci-
dated whether the effects of presenilin and presenilin mutantsNeuron 59, July 31, 2008 ª2008 Elsevier Inc. 193
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whether these effects are independent and perhaps rely on
uncleaved presenilin prior to its recruitment into the g-secretase
complex. It is curious that all mutations that affect calcium ho-
meostasis also alter g-secretase activity, whereas other preseni-
lin mutations not associated with FAD do not (Nelson et al.,
2007), yet removal of the protease function of presenilins does
not remove their effects on calcium (Tu et al., 2006).
Foskett and colleagues showed that modulation of the IP3
receptor could influence the production of Ab, with IP3 receptor
knockout resulting in marked reduction in Ab production
(Cheung et al., 2008). We have shown a similar result with knock-
down of SERCA, also resulting in reduced Ab production,
whereas overexpression of SERCA increases production (Green
et al., 2008). Given that SERCA pumps calcium into the ER and
the IP3 receptor releases calcium from the ER, it may be that it
is increased ER calcium release that leads to increased Ab—
SERCA activity will regulate ER release by setting the calcium
gradient across the ER membrane. Furthermore, calcium release
from the ER via the ryanodine receptor has also been shown to
increase Ab production (Querfurth et al., 1997). Taken together,
these results point to ER calcium regulation as being a critical
determinant for the production of Ab, in addition to plasma mem-
brane influx pathways such as with CALHM1. As these results
were not dependent upon the presence of FAD-linked mutant
presenilin, it suggests that calcium regulation may be relevant
to the progression of SAD and that targeting such channels
may offer a viable way to delay or prevent the onset of SAD.
Concluding Remarks
For the first time since the original calcium hypothesis of AD was
proposed, we have functional and genetic data that push
calcium to the crux for the sporadic version of the disease and
highlight several potential new therapeutic targets for both the
prevention and treatment of the disease. What is interesting is
that the crucial risk factor for SAD, aging, also involves significant
changes in calcium homeostasis (Toescu et al., 2004), which
could contribute to the initiation of the disease.
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